BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol 2017;35:691-712. [PMID: 28514998 DOI: 10.1016/j.tibtech.2017.04.007] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 24.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Yu S, Xu T, Bodenko V, Orlova A, Oroujeni M, Rinne SS, Tolmachev V, Vorobyeva A, Gräslund T. Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics 2022;14:1475. [PMID: 35890370 DOI: 10.3390/pharmaceutics14071475] [Reference Citation Analysis]
2 Lei Y, Shen Y, Zuo C, Lu L, Crommen J, Wang Q, Jiang Z. Emerging affinity ligands and support materials for the enrichment of monoclonal antibodies. TrAC Trends in Analytical Chemistry 2022. [DOI: 10.1016/j.trac.2022.116744] [Reference Citation Analysis]
3 Hu X, Li D, Fu Y, Zheng J, Feng Z, Cai J, Wang P. Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer. Front Oncol 2022;12:917439. [DOI: 10.3389/fonc.2022.917439] [Reference Citation Analysis]
4 Khatri B, Pramanick I, Malladi SK, Rajmani RS, Kumar S, Ghosh P, Sengupta N, Rahisuddin R, Kumar N, Kumaran S, Ringe RP, Varadarajan R, Dutta S, Chatterjee J. A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein. Nat Chem Biol 2022. [PMID: 35654847 DOI: 10.1038/s41589-022-01060-0] [Reference Citation Analysis]
5 Berg S, Suljovic D, Kärrberg L, Englund M, Bönisch H, Karlberg I, Van Zuydam N, Abrahamsson B, Hugerth AM, Davies N, Bergström CAS. Intestinal Absorption of FITC-Dextrans and Macromolecular Model Drugs in the Rat Intestinal Instillation Model. Mol Pharm 2022. [PMID: 35642793 DOI: 10.1021/acs.molpharmaceut.2c00261] [Reference Citation Analysis]
6 Rinne SS, Yin W, Borras AM, Abouzayed A, Leitao CD, Vorobyeva A, Löfblom J, Ståhl S, Orlova A, Gräslund T. Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. Biomedicines 2022;10:1293. [DOI: 10.3390/biomedicines10061293] [Reference Citation Analysis]
7 Grindel BJ, Engel BJ, Ong JN, Srinivasamani A, Liang X, Zacharias NM, Bast RC Jr, Curran MA, Takahashi TT, Roberts RW, Millward SW. Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol 2022. [PMID: 35611948 DOI: 10.1021/acschembio.2c00218] [Reference Citation Analysis]
8 Niu J, Cederstrand AJ, Eddinger GA, Yin B, Checco JW, Bingman CA, Outlaw VK, Gellman SH. Trimer-to-Monomer Disruption Mechanism for a Potent, Protease-Resistant Antagonist of Tumor Necrosis Factor-α Signaling. J Am Chem Soc 2022. [PMID: 35613436 DOI: 10.1021/jacs.1c13717] [Reference Citation Analysis]
9 Liu Y, Vorobyeva A, Orlova A, Konijnenberg MW, Xu T, Bragina O, Loftenius A, Rosander E, Frejd FY, Tolmachev V. Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics 2022;14:1092. [PMID: 35631678 DOI: 10.3390/pharmaceutics14051092] [Reference Citation Analysis]
10 Faresjö R, Lindberg H, Ståhl S, Löfblom J, Syvänen S, Sehlin D. Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies. Pharm Res 2022. [PMID: 35538266 DOI: 10.1007/s11095-022-03282-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zappala F, Higbee-Dempsey E, Jang B, Miller J, Yan L, Minutolo NG, Rosado González GT, Tsourkas A, Ozdemir BA. Rapid, site-specific labeling of "off-the-shelf" and native serum autoantibodies with T cell-redirecting domains. Sci Adv 2022;8:eabn4613. [PMID: 35522741 DOI: 10.1126/sciadv.abn4613] [Reference Citation Analysis]
12 Mcnulty MJ, Schwartz A, Delzio J, Karuppanan K, Jacobson A, Hart O, Dandekar A, Giritch A, Nandi S, Gleba Y, Mcdonald KA. Affinity Sedimentation and Magnetic Separation With Plant-Made Immunosorbent Nanoparticles for Therapeutic Protein Purification. Front Bioeng Biotechnol 2022;10:865481. [DOI: 10.3389/fbioe.2022.865481] [Reference Citation Analysis]
13 Bauer MS, Gruber S, Hausch A, Gomes PSFC, Milles LF, Nicolaus T, Schendel LC, Navajas PL, Procko E, Lietha D, Melo MCR, Bernardi RC, Gaub HE, Lipfert J. A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. Proc Natl Acad Sci U S A 2022;119:e2114397119. [PMID: 35312342 DOI: 10.1073/pnas.2114397119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Jia D, Wang F, Lu Y, Hu P, Wang R, Li G, Liu R, Li J, Liu H, Fan Q, Yuan F. Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121746] [Reference Citation Analysis]
15 Tan X, Yang J, Jiang J, Wang W, Ren J, Li Q, Xie Z, Chen X, Zhang L, Li W. Significant Growth Inhibition by a Bispecific Affibody Targeting Oncoprotein E7 in both HPV16 and 18 Positive Cervical Cancer in vitro and in vivo. Eur J Pharm Sci 2022;:106156. [PMID: 35245683 DOI: 10.1016/j.ejps.2022.106156] [Reference Citation Analysis]
16 Kumawat AK, Zegeye MM, Paramel GV, Baumgartner R, Gisterå A, Amegavie O, Hellberg S, Jin H, Caravaca AS, Söderström LÅ, Gudmundsdotter L, Frejd FY, Ljungberg LU, Olofsson PS, Ketelhuth DFJ, Sirsjö A. Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice. Front Cardiovasc Med 2022;9:831039. [DOI: 10.3389/fcvm.2022.831039] [Reference Citation Analysis]
17 Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 2022;7:39. [PMID: 35132063 DOI: 10.1038/s41392-021-00868-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
18 Huang Y, Li Y, Li X. Strategies for developing DNA-encoded libraries beyond binding assays. Nat Chem 2022;14:129-40. [PMID: 35121833 DOI: 10.1038/s41557-021-00877-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
19 Zhang G, Brown JS, Quartararo AJ, Li C, Tan X, Hanna S, Antilla S, Cowfer AE, Loas A, Pentelute BL. Rapid de novo discovery of peptidomimetic affinity reagents for human angiotensin converting enzyme 2. Commun Chem 2022;5. [DOI: 10.1038/s42004-022-00625-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhang D, Wang Z, Hu S, Chan NY, Liew HT, Lescar J, Tam JP, Liu CF. Asparaginyl Endopeptidase-Mediated Protein C-Terminal Hydrazinolysis for the Synthesis of Bioconjugates. Bioconjug Chem 2022. [PMID: 34985285 DOI: 10.1021/acs.bioconjchem.1c00551] [Reference Citation Analysis]
21 Xia X, Yang X, Huang W, Xia X, Yan D. Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers. Nanomicro Lett 2021;14:33. [PMID: 34902075 DOI: 10.1007/s40820-021-00762-9] [Reference Citation Analysis]
22 Akkapeddi P, Teng KW, Koide S. Monobodies as tool biologics for accelerating target validation and druggable site discovery. RSC Med Chem 2021;12:1839-53. [PMID: 34820623 DOI: 10.1039/d1md00188d] [Reference Citation Analysis]
23 Yamaguchi H, On J, Morita T, Suzuki T, Okada Y, Ono J, Evdokiou A. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. Int J Mol Sci 2021;22:12213. [PMID: 34830099 DOI: 10.3390/ijms222212213] [Reference Citation Analysis]
24 Sayyadi N, Zhand S, Razavi Bazaz S, Warkiani ME. Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes. Int J Mol Sci 2021;22:12014. [PMID: 34769444 DOI: 10.3390/ijms222112014] [Reference Citation Analysis]
25 Ito T, Nishi H, Kameda T, Yoshida M, Fukazawa R, Kawada S, Nakazawa H, Umetsu M. Combination Informatic and Experimental Approach for Selecting Scaffold Proteins for Development as Antibody Mimetics. Chem Lett 2021;50:1867-71. [DOI: 10.1246/cl.210443] [Reference Citation Analysis]
26 Ramm I, Sanchez-Fernandez A, Choi J, Lang C, Fransson J, Schagerlöf H, Wahlgren M, Nilsson L. The Impact of Glycerol on an Affibody Conformation and Its Correlation to Chemical Degradation. Pharmaceutics 2021;13:1853. [PMID: 34834267 DOI: 10.3390/pharmaceutics13111853] [Reference Citation Analysis]
27 Ren E, Liu C, Lv P, Wang J, Liu G. Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics. Adv Sci (Weinh) 2021;8:e2100460. [PMID: 34494387 DOI: 10.1002/advs.202100460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
28 Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, Sang S, Deng S. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. Molecules 2021;26:6482. [PMID: 34770887 DOI: 10.3390/molecules26216482] [Reference Citation Analysis]
29 Lindberg J, Nilvebrant J, Nygren PÅ, Lehmann F. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules 2021;26:6042. [PMID: 34641586 DOI: 10.3390/molecules26196042] [Reference Citation Analysis]
30 Yang X, Xia X, Xia XX, Sun Z, Yan D. Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein. Mol Pharm 2021;18:3854-61. [PMID: 34543035 DOI: 10.1021/acs.molpharmaceut.1c00483] [Reference Citation Analysis]
31 Woloschuk RM, Reed PMM, Jaikaran ASI, Demmans KZ, Youn J, Kanelis V, Uppalapati M, Woolley GA. Structure-based design of a photoswitchable affibody scaffold. Protein Sci 2021;30:2359-72. [PMID: 34590762 DOI: 10.1002/pro.4196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Rinne SS, Leitao CD, Abouzayed A, Vorobyeva A, Tolmachev V, Ståhl S, Löfblom J, Orlova A. HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. Cancers (Basel) 2021;13:4791. [PMID: 34638277 DOI: 10.3390/cancers13194791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Jia D, Wang F, Yang Y, Hu P, Song H, Lu Y, Wang R, Li G, Liu R, Li J, Yuan F. Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models. J Pharm Sci 2021:S0022-3549(21)00488-3. [PMID: 34547305 DOI: 10.1016/j.xphs.2021.09.018] [Reference Citation Analysis]
34 Kamara S, Guo Y, Mao S, Ye X, Li Q, Zheng M, Zhu J, Zhang J, Du W, Chen J, Zhu S, Zhang L. Novel EBV LMP1 C-terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma. Appl Microbiol Biotechnol 2021;105:7283-93. [PMID: 34505914 DOI: 10.1007/s00253-021-11559-6] [Reference Citation Analysis]
35 Molavipordanjani S, Hosseinimehr SJ. The Radiolabeled HER3 Targeting Molecules for Tumor Imaging. Iran J Pharm Res 2021;20:141-52. [PMID: 34400948 DOI: 10.22037/ijpr.2021.114677.14991] [Reference Citation Analysis]
36 Wang X, Luo D, Basilion JP. Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers. Cancers (Basel) 2021;13:2992. [PMID: 34203805 DOI: 10.3390/cancers13122992] [Reference Citation Analysis]
37 Xi Z, Liu X, Lin R, Persons JD, Ilina TV, Li W, Dimitrov DS, Ishima R. The reduced form of the antibody CH2 domain. Protein Sci 2021;30:1895-903. [PMID: 34107549 DOI: 10.1002/pro.4142] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Liu Y, Vorobyeva A, Xu T, Orlova A, Loftenius A, Bengtsson T, Jonasson P, Tolmachev V, Frejd FY. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics 2021;13:839. [PMID: 34200197 DOI: 10.3390/pharmaceutics13060839] [Reference Citation Analysis]
39 Li Y, Li W, Xu Z. Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool. Mar Drugs 2021;19:311. [PMID: 34072121 DOI: 10.3390/md19060311] [Reference Citation Analysis]
40 Zhu J, Kamara S, Wang Q, Guo Y, Li Q, Wang L, Chen J, Du Q, Du W, Chen S, Zhu S, Chen J, Chu M, Zhang L. Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells. Front Cell Dev Biol 2021;9:677867. [PMID: 34109181 DOI: 10.3389/fcell.2021.677867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kim H, Jin S, Choi H, Kang M, Park SG, Jun H, Cho H, Kang S. Target-switchable Gd(III)-DOTA/protein cage nanoparticle conjugates with multiple targeting affibody molecules as target selective T1 contrast agents for high-field MRI. J Control Release 2021;335:269-80. [PMID: 34044091 DOI: 10.1016/j.jconrel.2021.05.029] [Reference Citation Analysis]
42 Westerlund K, Myrhammar A, Tano H, Gestin M, Karlström AE. Stability Enhancement of a Dimeric HER2-Specific Affibody Molecule through Sortase A-Catalyzed Head-to-Tail Cyclization. Molecules 2021;26:2874. [PMID: 34066245 DOI: 10.3390/molecules26102874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Huang Y, Li X. Recent Advances on the Selection Methods of DNA-Encoded Libraries. Chembiochem 2021;22:2384-97. [PMID: 33891355 DOI: 10.1002/cbic.202100144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Berland L, Kim L, Abousaway O, Mines A, Mishra S, Clark L, Hofman P, Rashidian M. Nanobodies for Medical Imaging: About Ready for Prime Time? Biomolecules 2021;11:637. [PMID: 33925941 DOI: 10.3390/biom11050637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Zhang C, Ötjengerdes RM, Roewe J, Mejias R, Marschall ALJ. Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. BioDrugs 2020;34:435-62. [PMID: 32301049 DOI: 10.1007/s40259-020-00419-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Zhong X, D'Antona AM. Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. Antibodies (Basel) 2021;10:13. [PMID: 33808165 DOI: 10.3390/antib10020013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Volk AL, Mebrahtu A, Ko BK, Lundqvist M, Karlander M, Lee HJ, Frejd FY, Kim KT, Lee JS, Rockberg J. Bispecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule Combination. Drugs R D 2021;21:157-68. [PMID: 33721246 DOI: 10.1007/s40268-021-00339-2] [Reference Citation Analysis]
48 Oroujeni M, Rinne SS, Vorobyeva A, Loftenius A, Feldwisch J, Jonasson P, Chernov V, Orlova A, Frejd FY, Tolmachev V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. Int J Mol Sci 2021;22:2770. [PMID: 33803361 DOI: 10.3390/ijms22052770] [Reference Citation Analysis]
49 Yocum HC, Pham A, Da Silva NA. Successful Enzyme Colocalization Strategies in Yeast for Increased Synthesis of Non-native Products. Front Bioeng Biotechnol 2021;9:606795. [PMID: 33634084 DOI: 10.3389/fbioe.2021.606795] [Reference Citation Analysis]
50 Oroujeni M, Xu T, Gagnon K, Rinne SS, Weis J, Garousi J, Andersson KG, Löfblom J, Orlova A, Tolmachev V. The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. Pharmaceutics 2021;13:292. [PMID: 33672373 DOI: 10.3390/pharmaceutics13020292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Li Q, Li W, Xu K, Xing Y, Shi H, Jing Z, Li S, Hong Z. PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates. Int J Mol Sci 2021;22:1540. [PMID: 33546481 DOI: 10.3390/ijms22041540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Li M, Shi W, Yang J, Wang Q, Dong H, Chen J, Zhang L, Zhu S. Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP. Appl Microbiol Biotechnol 2021;105:1477-87. [PMID: 33521848 DOI: 10.1007/s00253-021-11128-x] [Reference Citation Analysis]
53 Tano H, Oroujeni M, Vorobyeva A, Westerlund K, Liu Y, Xu T, Vasconcelos D, Orlova A, Karlström AE, Tolmachev V. Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. Cancers (Basel) 2021;13:500. [PMID: 33525578 DOI: 10.3390/cancers13030500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Altai M, Vorobyeva A, Tolmachev V, Karlström AE, Westerlund K. Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting. Methods Mol Biol 2020;2105:283-304. [PMID: 32088878 DOI: 10.1007/978-1-0716-0243-0_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Tolmachev V, Orlova A, Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Semin Cancer Biol 2021;72:185-97. [PMID: 33465471 DOI: 10.1016/j.semcancer.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Xu T, Ding H, Vorobyeva A, Oroujeni M, Orlova A, Tolmachev V, Gräslund T. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers (Basel) 2020;13:E85. [PMID: 33396753 DOI: 10.3390/cancers13010085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Dhritlahre RK, Saneja A. Recent advances in HER2-targeted delivery for cancer therapy. Drug Discov Today 2021;26:1319-29. [PMID: 33359114 DOI: 10.1016/j.drudis.2020.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Wang W, Tan X, Jiang J, Cai Y, Feng F, Zhang L, Li W. Targeted biological effect of an affitoxin composed of an HPV16E7 affibody fused with granzyme B (ZHPV16E7-GrB) against cervical cancer in vitro and in vivo. Curr Cancer Drug Targets 2020. [PMID: 33292132 DOI: 10.2174/1568009620666201207145720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol 2021;18:244-56. [PMID: 33277626 DOI: 10.1038/s41571-020-00449-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
60 Myrhammar A, Vorobyeva A, Westerlund K, Yoneoka S, Orlova A, Tsukahara T, Tolmachev V, Karlström AE, Altai M. Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. Sci Rep 2020;10:20777. [PMID: 33247180 DOI: 10.1038/s41598-020-77523-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Fernandes CSM, Pina AS, Roque ACA. Affinity-triggered hydrogels: Developments and prospects in biomaterials science. Biomaterials 2021;268:120563. [PMID: 33276200 DOI: 10.1016/j.biomaterials.2020.120563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Galindo Casas M, Stargardt P, Mairhofer J, Wiltschi B. Decoupling Protein Production from Cell Growth Enhances the Site-Specific Incorporation of Noncanonical Amino Acids in E. coli. ACS Synth Biol 2020;9:3052-66. [PMID: 33150786 DOI: 10.1021/acssynbio.0c00298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Liu J, Cui D, Jiang Y, Li Y, Liu Z, Tao L, Zhao Q, Diao A. Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein. Int J Biol Macromol 2021;166:884-92. [PMID: 33157139 DOI: 10.1016/j.ijbiomac.2020.10.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
64 Güler R, Svedmark SF, Abouzayed A, Orlova A, Löfblom J. Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches. Sci Rep 2020;10:18148. [PMID: 33097752 DOI: 10.1038/s41598-020-74560-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Wilkes J, Scott-Tucker A, Wright M, Crabbe T, Scrutton NS. Exploiting Single Domain Antibodies as Regulatory Parts to Modulate Monoterpenoid Production in E. coli. ACS Synth Biol 2020;9:2828-39. [PMID: 32927940 DOI: 10.1021/acssynbio.0c00375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Peckys DB, Quint C, Jonge N. Determining the Efficiency of Single Molecule Quantum Dot Labeling of HER2 in Breast Cancer Cells. Nano Lett 2020;20:7948-55. [PMID: 33034459 DOI: 10.1021/acs.nanolett.0c02644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Tsang VTC, Li X, Wong TTW. A Review of Endogenous and Exogenous Contrast Agents Used in Photoacoustic Tomography with Different Sensing Configurations. Sensors (Basel) 2020;20:E5595. [PMID: 33003566 DOI: 10.3390/s20195595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
68 Koudrina A, DeRosa MC. Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents. ACS Omega 2020;5:22691-701. [PMID: 32954116 DOI: 10.1021/acsomega.0c02650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
69 Shakeran Z, Javadi-Zarnaghi F, Emamzadeh R. Novel luminescent affiprobes for molecular detection of Staphylococcus aureus using flow cytometry. J Appl Microbiol 2021;130:493-503. [PMID: 32738017 DOI: 10.1111/jam.14799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Garousi J, Orlova A, Frejd FY, Tolmachev V. Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. EJNMMI Radiopharm Chem 2020;5:16. [PMID: 32577943 DOI: 10.1186/s41181-020-00094-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
71 Rabiee N, Ahmadi S, Arab Z, Bagherzadeh M, Safarkhani M, Nasseri B, Rabiee M, Tahriri M, Webster TJ, Tayebi L. Aptamer Hybrid Nanocomplexes as Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review. Int J Nanomedicine 2020;15:4237-56. [PMID: 32606675 DOI: 10.2147/IJN.S248736] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
72 Leitao CD, Rinne SS, Altai M, Vorontsova O, Dunås F, Jonasson P, Tolmachev V, Löfblom J, Ståhl S, Orlova A. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. Pharmaceutics 2020;12:E551. [PMID: 32545760 DOI: 10.3390/pharmaceutics12060551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Soriano A, Soriano M, Espinosa G, Manna R, Emmi G, Cantarini L, Hernández-Rodríguez J. Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Front Immunol 2020;11:865. [PMID: 32655539 DOI: 10.3389/fimmu.2020.00865] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
74 Shetab Boushehri MA, Dietrich D, Lamprecht A. Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art. Pharmaceutics 2020;12:E510. [PMID: 32503171 DOI: 10.3390/pharmaceutics12060510] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
75 Qi S, Hoppmann S, Xu Y, Cheng Z. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Mol Imaging Biol 2019;21:907-16. [PMID: 30617730 DOI: 10.1007/s11307-018-01310-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
76 Zhao N, Ding B, Zhang Y, Klockow JL, Lau K, Chin FT, Cheng Z, Liu H. Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy. J Control Release 2020;324:330-40. [PMID: 32450093 DOI: 10.1016/j.jconrel.2020.05.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
77 Ding H, Altai M, Yin W, Lindbo S, Liu H, Garousi J, Xu T, Orlova A, Tolmachev V, Hober S, Gräslund T. HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. Pharmaceutics 2020;12:E391. [PMID: 32344762 DOI: 10.3390/pharmaceutics12040391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Meister SW, Hjelm LC, Dannemeyer M, Tegel H, Lindberg H, Ståhl S, Löfblom J. An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor. Int J Mol Sci 2020;21:E2999. [PMID: 32340383 DOI: 10.3390/ijms21082999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Baloche V, Ferrand FR, Makowska A, Even C, Kontny U, Busson P. Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. Expert Opin Ther Targets 2020;24:545-58. [PMID: 32249657 DOI: 10.1080/14728222.2020.1751820] [Reference Citation Analysis]
80 Zhu J, Kamara S, Cen D, Tang W, Gu M, Ci X, Chen J, Wang L, Zhu S, Jiang P, Chen S, Xue X, Zhang L. Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells. Cell Death Dis 2020;11:213. [PMID: 32238802 DOI: 10.1038/s41419-020-2410-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
81 Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
82 Rinne SS, Dahlsson Leitao C, Saleh-Nihad Z, Mitran B, Tolmachev V, Ståhl S, Löfblom J, Orlova A. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. Int J Mol Sci 2020;21:E1972. [PMID: 32183096 DOI: 10.3390/ijms21061972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Karyagina TS, Ulasov AV, Slastnikova TA, Rosenkranz AA, Lupanova TN, Khramtsov YV, Georgiev GP, Sobolev AS. Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody. Front Pharmacol 2020;11:176. [PMID: 32194412 DOI: 10.3389/fphar.2020.00176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
84 Perkins LA, Bruchez MP. Fluorogen activating protein toolset for protein trafficking measurements. Traffic 2020;21:333-48. [PMID: 32080949 DOI: 10.1111/tra.12722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
85 Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol 2019;15:197-207. [PMID: 30814691 DOI: 10.1038/s41584-019-0188-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
86 Rinne SS, Xu T, Dahlsson Leitao C, Ståhl S, Löfblom J, Orlova A, Tolmachev V, Vorobyeva A. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. Int J Mol Sci 2020;21:E1312. [PMID: 32075258 DOI: 10.3390/ijms21041312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
87 Zhang C, Han M, Zhang F, Yang X, Du J, Zhang H, Li W, Chen S. Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle. Int J Nanomedicine 2020;15:885-900. [PMID: 32103944 DOI: 10.2147/IJN.S231144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Myrhammar A, Rosik D, Karlström AE. Photocontrolled Reversible Binding between the Protein A-Derived Z Domain and Immunoglobulin G. Bioconjugate Chem 2020;31:622-30. [DOI: 10.1021/acs.bioconjchem.9b00786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Kunishige R, Kano F, Murata M. The cell resealing technique for manipulating, visualizing, and elucidating molecular functions in living cells. Biochimica et Biophysica Acta (BBA) - General Subjects 2020;1864:129329. [DOI: 10.1016/j.bbagen.2019.03.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
90 Crook ZR, Nairn NW, Olson JM. Miniproteins as a Powerful Modality in Drug Development. Trends Biochem Sci 2020;45:332-46. [PMID: 32014389 DOI: 10.1016/j.tibs.2019.12.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
91 Filik H, Avan AA. Electrochemical immunosensors for the detection of cytokine tumor necrosis factor alpha: A review. Talanta 2020;211:120758. [PMID: 32070602 DOI: 10.1016/j.talanta.2020.120758] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
92 Zhu S, Chen J, Xiong Y, Kamara S, Gu M, Tang W, Chen S, Dong H, Xue X, Zheng ZM, Zhang L. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma. PLoS Pathog 2020;16:e1008223. [PMID: 31905218 DOI: 10.1371/journal.ppat.1008223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
93 Li R, Li Z, Feng Y, Yang H, Shi Q, Tao Z, Cheng J, Lu X. PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis. Apoptosis 2020;25:105-19. [DOI: 10.1007/s10495-019-01583-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Eggenstein E, Richter A, Skerra A. FluoroCalins: engineered lipocalins with novel binding functions fused to a fluorescent protein for applications in biomolecular imaging and detection. Protein Eng Des Sel 2019;32:289-96. [PMID: 31927584 DOI: 10.1093/protein/gzz047] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
95 Huizing FJ, Garousi J, Lok J, Franssen G, Hoeben BAW, Frejd FY, Boerman OC, Bussink J, Tolmachev V, Heskamp S. CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. Sci Rep 2019;9:18898. [PMID: 31827111 DOI: 10.1038/s41598-019-54824-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
96 Güler R, Thatikonda N, Ghani HA, Hedhammar M, Löfblom J. VEGFR2-Specific Ligands Based on Affibody Molecules Demonstrate Agonistic Effects when Tetrameric in the Soluble Form or Immobilized via Spider Silk. ACS Biomater Sci Eng 2019;5:6474-84. [PMID: 33417800 DOI: 10.1021/acsbiomaterials.9b00994] [Reference Citation Analysis]
97 Gebauer M, Skerra A. Engineering of binding functions into proteins. Current Opinion in Biotechnology 2019;60:230-41. [DOI: 10.1016/j.copbio.2019.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
98 Yamaguchi H, Pantarat N, Suzuki T, Evdokiou A. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer. Int J Mol Sci 2019;20:E5835. [PMID: 31757056 DOI: 10.3390/ijms20235835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
99 Jing L, Liu J, Cui D, Li Y, Liu Z, Tao L, Zhao Q, Diao A. Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint. Protein Expr Purif 2020;166:105520. [PMID: 31644959 DOI: 10.1016/j.pep.2019.105520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Garousi J, Huizing FJ, Vorobyeva A, Mitran B, Andersson KG, Leitao CD, Frejd FY, Löfblom J, Bussink J, Orlova A, Heskamp S, Tolmachev V. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Sci Rep 2019;9:14907. [PMID: 31624303 DOI: 10.1038/s41598-019-51445-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
101 Xu Y, Wang L, Pan D, Yu C, Mi B, Huang Q, Sheng J, Yan J, Wang X, Yang R, Yang M. PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients. Br J Radiol 2019;92:20190425. [PMID: 31593482 DOI: 10.1259/bjr.20190425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Ding H, Altai M, Rinne SS, Vorobyeva A, Tolmachev V, Gräslund T, Orlova A. Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. Cancers (Basel) 2019;11:E1168. [PMID: 31416167 DOI: 10.3390/cancers11081168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Pourshohod A, Jamalan M, Zeinali M, Ghanemi M, kheirollah A. Enhancement of X-ray radiotherapy by specific delivery of ZHER2 affibody-conjugated gold nanoparticles to HER2-positive malignant cells. Journal of Drug Delivery Science and Technology 2019;52:934-41. [DOI: 10.1016/j.jddst.2019.05.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Peltomaa R, Benito-Peña E, Barderas R, Moreno-Bondi MC. Phage Display in the Quest for New Selective Recognition Elements for Biosensors. ACS Omega 2019;4:11569-80. [PMID: 31460264 DOI: 10.1021/acsomega.9b01206] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
105 Bam R, Laffey M, Nottberg K, Lown PS, Hackel BJ, Wilson KE. Affibody-Indocyanine Green Based Contrast Agent for Photoacoustic and Fluorescence Molecular Imaging of B7-H3 Expression in Breast Cancer. Bioconjug Chem 2019;30:1677-89. [PMID: 31082216 DOI: 10.1021/acs.bioconjchem.9b00239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
106 Rosestedt M, Andersson KG, Rinne SS, Leitao CD, Mitran B, Vorobyeva A, Ståhl S, Löfblom J, Tolmachev V, Orlova A. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. Sci Rep 2019;9:6779. [PMID: 31043683 DOI: 10.1038/s41598-019-43145-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
107 Cai H, Shi Q, Tang Y, Chen L, Chen Y, Tao Z, Yang H, Xie F, Wu X, Liu N, Yang Y, Wu H, Tian R, Lu X, Li L. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule. Mol Pharmaceutics 2019;16:1950-7. [DOI: 10.1021/acs.molpharmaceut.8b01317] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
108 Boutajangout A, Lindberg H, Awwad A, Paul A, Baitalmal R, Almokyad I, Höidén-Guthenberg I, Gunneriusson E, Frejd FY, Härd T, Löfblom J, Ståhl S, Wisniewski T. Affibody-Mediated Sequestration of Amyloid β Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model. Front Aging Neurosci 2019;11:64. [PMID: 30967771 DOI: 10.3389/fnagi.2019.00064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
109 Deyev S, Vorobyeva A, Schulga A, Proshkina G, Güler R, Löfblom J, Mitran B, Garousi J, Altai M, Buijs J, Chernov V, Orlova A, Tolmachev V. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. Mol Pharm 2019;16:995-1008. [PMID: 30608701 DOI: 10.1021/acs.molpharmaceut.8b00922] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
110 Hober S, Lindbo S, Nilvebrant J. Bispecific applications of non-immunoglobulin scaffold binders. Methods 2019;154:143-52. [DOI: 10.1016/j.ymeth.2018.09.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
111 Tsuchimochi M, Yamaguchi H, Hayama K, Okada Y, Kawase T, Suzuki T, Tsubokawa N, Wada N, Ochiai A, Fujii S, Fujii H. Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach. Int J Mol Sci 2019;20:E427. [PMID: 30669481 DOI: 10.3390/ijms20020427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
112 Lagoutte P, Lugari A, Elie C, Potisopon S, Donnat S, Mignon C, Mariano N, Troesch A, Werle B, Stadthagen G. Combination of ribosome display and next generation sequencing as a powerful method for identification of affibody binders against β-lactamase CTX-M15. N Biotechnol 2019;50:60-9. [PMID: 30634000 DOI: 10.1016/j.nbt.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Pan Y, Yang Z, Xu Y, Bai Z, Pan D, Yang R, Wang L, Guan W, Yang M. Targeting HER2-positive gastric cancer with a novel 18 F-labeled Z HER2:342 probe. RSC Adv 2019;9:10990-8. [DOI: 10.1039/c8ra10271f] [Reference Citation Analysis]
114 Zhang Y, Ni Q, Xu C, Wan B, Geng Y, Zheng G, Yang Z, Tao J, Zhao Y, Wen J, Zhang J, Wang S, Tang Y, Li Y, Zhang Q, Liu L, Teng Z, Lu G. Smart Bacterial Magnetic Nanoparticles for Tumor-Targeting Magnetic Resonance Imaging of HER2-Positive Breast Cancers. ACS Appl Mater Interfaces 2019;11:3654-65. [PMID: 30495920 DOI: 10.1021/acsami.8b15838] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
115 Richards DA. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. Drug Discovery Today: Technologies 2018;30:35-46. [DOI: 10.1016/j.ddtec.2018.10.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
116 Wagner HJ, Wehrle S, Weiss E, Cavallari M, Weber W. A Two-Step Approach for the Design and Generation of Nanobodies. Int J Mol Sci 2018;19:E3444. [PMID: 30400198 DOI: 10.3390/ijms19113444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
117 Altai M, Leitao CD, Rinne SS, Vorobyeva A, Atterby C, Ståhl S, Tolmachev V, Löfblom J, Orlova A. Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. Cells 2018;7:E164. [PMID: 30314301 DOI: 10.3390/cells7100164] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
118 Andersson KG, Persson J, Ståhl S, Löfblom J. Autotransporter-Mediated Display of a Naïve Affibody Library on the Outer Membrane of Escherichia coli. Biotechnol J 2019;14:e1800359. [PMID: 30179307 DOI: 10.1002/biot.201800359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
119 Oroujeni M, Garousi J, Andersson KG, Löfblom J, Mitran B, Orlova A, Tolmachev V. Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. Cells 2018;7:E141. [PMID: 30231504 DOI: 10.3390/cells7090141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
120 Altai M, Liu H, Ding H, Mitran B, Edqvist PH, Tolmachev V, Orlova A, Gräslund T. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. J Control Release 2018;288:84-95. [PMID: 30172673 DOI: 10.1016/j.jconrel.2018.08.040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
121 Nabil G, Bhise K, Sau S, Atef M, El-Banna HA, Iyer AK. Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation. Drug Discov Today 2019;24:462-91. [PMID: 30121330 DOI: 10.1016/j.drudis.2018.08.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
122 Yanai A, Harada R, Iwata R, Yoshikawa T, Ishikawa Y, Furumoto S, Ishida T, Yanai K. Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule. Mol Imaging Biol 2019;21:529-37. [DOI: 10.1007/s11307-018-1266-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
123 Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. Theranostics 2018;8:4462-76. [PMID: 30214632 DOI: 10.7150/thno.24395] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
124 Orlova A, Bass TZ, Rinne SS, Leitao CD, Rosestedt M, Atterby C, Gudmundsdotter L, Frejd FY, Löfblom J, Tolmachev V, Ståhl S. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. Mol Pharm 2018;15:3394-403. [PMID: 29995421 DOI: 10.1021/acs.molpharmaceut.8b00393] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
125 van Kasteren SI, Neefjes J, Ovaa H. Creating molecules that modulate immune responses. Nat Rev Chem 2018;2:184-93. [DOI: 10.1038/s41570-018-0023-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
126 Vorobyeva A, Westerlund K, Mitran B, Altai M, Rinne S, Sörensen J, Orlova A, Tolmachev V, Karlström AE. Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. Sci Rep 2018;8:9643. [PMID: 29942011 DOI: 10.1038/s41598-018-27886-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
127 Zhu S, Zhu J, Song Y, Chen J, Wang L, Zhou M, Jiang P, Li W, Xue X, Zhao KN, Zhang L. Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer. Appl Microbiol Biotechnol 2018;102:7429-39. [PMID: 29938318 DOI: 10.1007/s00253-018-9167-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
128 Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. Designer Oncolytic Adenovirus: Coming of Age. Cancers (Basel) 2018;10:E201. [PMID: 29904022 DOI: 10.3390/cancers10060201] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
129 Spicer CD, Jumeaux C, Gupta B, Stevens MM. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. Chem Soc Rev 2018;47:3574-620. [PMID: 29479622 DOI: 10.1039/c7cs00877e] [Cited by in Crossref: 190] [Cited by in F6Publishing: 50] [Article Influence: 47.5] [Reference Citation Analysis]
130 Qi J, Li X, Peng H, Cook EM, Dadashian EL, Wiestner A, Park H, Rader C. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. Proc Natl Acad Sci U S A 2018;115:E5467-76. [PMID: 29844189 DOI: 10.1073/pnas.1719905115] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
131 Ye D, Li Y, Gu N. Magnetic labeling of natural lipid encapsulations with iron-based nanoparticles. Nano Res 2018;11:2970-91. [DOI: 10.1007/s12274-018-1980-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Tsai WK, Wu AM. Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 2018;61:693-714. [PMID: 29537104 DOI: 10.1002/jlcr.3622] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
133 Oroujeni M, Andersson KG, Steinhardt X, Altai M, Orlova A, Mitran B, Vorobyeva A, Garousi J, Tolmachev V, Löfblom J. Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules. Amino Acids 2018;50:981-94. [PMID: 29728916 DOI: 10.1007/s00726-018-2571-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
134 Pérez-Treviño P, la Cerda HH, Pérez-Treviño J, Fajardo-Ramírez OR, García N, Altamirano J. 3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis. Transl Oncol 2018;11:672-85. [PMID: 29627705 DOI: 10.1016/j.tranon.2018.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Deonarain MP, Yahioglu G, Stamati I, Pomowski A, Clarke J, Edwards BM, Diez-Posada S, Stewart AC. Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours? Antibodies (Basel) 2018;7:E16. [PMID: 31544868 DOI: 10.3390/antib7020016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
136 Yang H, Feng Y, Cai H, Jia D, Li H, Tao Z, Zhong Y, Li Z, Shi Q, Wan L, Li L, Lu X. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects. Theranostics 2018;8:2459-76. [PMID: 29721092 DOI: 10.7150/thno.23880] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
137 Waters EA, Shusta EV. The variable lymphocyte receptor as an antibody alternative. Curr Opin Biotechnol 2018;52:74-9. [PMID: 29597074 DOI: 10.1016/j.copbio.2018.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
138 Verdino P, Atwell S, Demarest SJ. Emerging trends in bispecific antibody and scaffold protein therapeutics. Current Opinion in Chemical Engineering 2018;19:107-23. [DOI: 10.1016/j.coche.2018.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
139 Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets 2018;22:263-77. [PMID: 29447008 DOI: 10.1080/14728222.2018.1439924] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 25.5] [Reference Citation Analysis]
140 Westerlund K, Altai M, Mitran B, Konijnenberg M, Oroujeni M, Atterby C, de Jong M, Orlova A, Mattsson J, Micke P, Karlström AE, Tolmachev V. Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. J Nucl Med 2018;59:1092-8. [PMID: 29439013 DOI: 10.2967/jnumed.118.208348] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
141 Murakami M, Kano F, Murata M. LLO-mediated Cell Resealing System for Analyzing Intracellular Activity of Membrane-impermeable Biopharmaceuticals of Mid-sized Molecular Weight. Sci Rep 2018;8:1946. [PMID: 29386585 DOI: 10.1038/s41598-018-20482-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
142 Harmansa S, Affolter M. Protein binders and their applications in developmental biology. Development 2018;145:dev148874. [PMID: 29374062 DOI: 10.1242/dev.148874] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
143 Takeuchi T, Sunayama H. Beyond natural antibodies – a new generation of synthetic antibodies created by post-imprinting modification of molecularly imprinted polymers. Chem Commun 2018;54:6243-51. [DOI: 10.1039/c8cc02923g] [Cited by in Crossref: 45] [Cited by in F6Publishing: 5] [Article Influence: 11.3] [Reference Citation Analysis]
144 Bang J, Park H, Choi WI, Sung D, Lee JH, Lee KY, Kim S. Sensitive detection of dengue virus NS1 by highly stable affibody-functionalized gold nanoparticles. New J Chem 2018;42:12607-14. [DOI: 10.1039/c8nj02244e] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
145 Östman A. PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment. Adv Drug Deliv Rev 2017;121:117-23. [PMID: 28970051 DOI: 10.1016/j.addr.2017.09.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
146 Nilsson A, Lindgren J, Eriksson Karlström A. Intramolecular Thioether Crosslinking to Increase the Proteolytic Stability of Affibody Molecules. Chembiochem 2017;18:2056-62. [PMID: 28836374 DOI: 10.1002/cbic.201700350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
147 Löfblom J, Rosenstein R, Nguyen MT, Ståhl S, Götz F. Staphylococcus carnosus: from starter culture to protein engineering platform. Appl Microbiol Biotechnol 2017;101:8293-307. [PMID: 28971248 DOI: 10.1007/s00253-017-8528-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
148 Lau J, Lin KS, Bénard F. Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics 2017;7:4322-39. [PMID: 29158829 DOI: 10.7150/thno.21848] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]